- Home
- ACRS vs CDXS Comparison
ACRS vs CDXS Comparison
Compare ACRS & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- CDXS
- Stock Information
- Founded
- ACRS 2012
- CDXS 2002
- Country
- ACRS United States
- CDXS United States
- Employees
- ACRS N/A
- CDXS N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- CDXS Major Chemicals
- Sector
- ACRS Health Care
- CDXS Industrials
- Exchange
- ACRS Nasdaq
- CDXS Nasdaq
- Market Cap
- ACRS 198.2M
- CDXS 216.6M
- IPO Year
- ACRS 2015
- CDXS 2010
- Fundamental
- Price
- ACRS $1.89
- CDXS $2.64
- Analyst Decision
- ACRS Strong Buy
- CDXS Buy
- Analyst Count
- ACRS 9
- CDXS 2
- Target Price
- ACRS $9.25
- CDXS $11.00
- AVG Volume (30 Days)
- ACRS 1.1M
- CDXS 517.3K
- Earning Date
- ACRS 11-05-2025
- CDXS 10-30-2025
- Dividend Yield
- ACRS N/A
- CDXS N/A
- EPS Growth
- ACRS N/A
- CDXS N/A
- EPS
- ACRS N/A
- CDXS N/A
- Revenue
- ACRS $16,789,000.00
- CDXS $57,164,000.00
- Revenue This Year
- ACRS N/A
- CDXS $12.88
- Revenue Next Year
- ACRS $7.02
- CDXS $21.64
- P/E Ratio
- ACRS N/A
- CDXS N/A
- Revenue Growth
- ACRS N/A
- CDXS N/A
- 52 Week Low
- ACRS $1.05
- CDXS $1.90
- 52 Week High
- ACRS $5.17
- CDXS $6.08
- Technical
- Relative Strength Index (RSI)
- ACRS 48.51
- CDXS 52.60
- Support Level
- ACRS $1.81
- CDXS $2.51
- Resistance Level
- ACRS $1.94
- CDXS $2.73
- Average True Range (ATR)
- ACRS 0.09
- CDXS 0.11
- MACD
- ACRS -0.01
- CDXS 0.03
- Stochastic Oscillator
- ACRS 27.51
- CDXS 56.80
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About CDXS Codexis Inc.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.